SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
DEF 14A	Sep 28, 2026	Sep 28, 2026	View filing
8-K	Sep 14, 2026	Sep 11, 2026	View filing
424B5	Sep 14, 2026	Sep 11, 2026	View filing
SC 13G	Sep 3, 2026	Sep 3, 2026	View filing
4	Aug 28, 2026	Aug 28, 2026	View filing
4	Aug 28, 2026	Aug 28, 2026	View filing
4	Aug 28, 2026	Aug 28, 2026	View filing
4	Aug 28, 2026	Aug 28, 2026	View filing
SC 13G	Aug 19, 2026	Aug 19, 2026	View filing
S-1/A	Aug 14, 2026	Aug 14, 2026	View filing
10-K	Aug 13, 2026	Aug 12, 2026	View filing
SC 13G/A	Aug 7, 2026	Aug 7, 2026	View filing
SC 13G	Aug 7, 2026	Aug 7, 2026	View filing
FWP	Aug 7, 2026	Aug 7, 2026	View filing
FWP	Aug 6, 2026	Aug 6, 2026	View filing
FWP	Aug 6, 2026	Aug 6, 2026	View filing
S-1/A	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
S-1/A	Jul 31, 2026	Jul 31, 2026	View filing
S-1	Jul 17, 2026	Jul 17, 2026	View filing
EFFECT	Jun 29, 2026	Jun 30, 2026	View filing
S-3	Jun 18, 2026	Jun 18, 2026	View filing
10-Q	May 11, 2026	May 11, 2026	View filing
SC 13D	Mar 25, 2026	Mar 25, 2026	View filing
10-Q	Feb 6, 2026	Feb 6, 2026	View filing
4	Jan 9, 2026	Jan 9, 2026	View filing
4	Jan 9, 2026	Jan 9, 2026	View filing
4	Jan 9, 2026	Jan 9, 2026	View filing
4	Jan 9, 2026	Jan 9, 2026	View filing
4	Jan 9, 2026	Jan 9, 2026	View filing

About BioVie Inc.

BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.

Carson City, NV

13 employees

bioviepharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Cuong Viet Do

View full financials